International Clinical Trial: RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07735624) titled 'RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer' on July 24.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Dana-Farber Cancer Institute

Condition: Early Rectal Cancer Stage I Rectal Cancer Microsatellite Stable Rectal Carcinoma

Intervention: Drug: Botensilimab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 2026

Target Sample Size: 16

Countries of Recruitment: United States

To know more, visit https://cl...